Celia Cifuentes1, María Mancebo-Hernández1, Elisabet Pérez-Navarro1, Eva Recio1, Patricia Monje-Agudo1, Adoración Valiente2, Juan A Pineda3. 1. Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, España. 2. Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, España; Unidad Clínica Intercentros de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Macarena, Sevilla, España. 3. Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, España. Electronic address: japineda@telefonica.net.
Abstract
BACKGROUND: The prevalence of hepatitisC is decreasing among new diagnoses of HIV/HCV coinfection in Spain. The increasing use of the HCV treatment could have changed the HCV genotype distribution. The aim of this study is to analyze changes in the prevalence of HCV coinfection and in HCV genotype distribution among HIV-infected patients. METHODS: A serial cross-sectional study was conducted that included all HIV-infected patients who attended the Outpatient Clinic of a hospital in Andalusia, between September 2008 and February 2009 (first period), and between January 2013 and June 2013 (second period). RESULTS: A total of 520 and 651 patients were included in the first and second period, respectively. The risk factors of HCV infection in the first vs. second period were: IDU, 319 (61%) vs. 348 (53%); heterosexual contact, 111 (21%) vs. 135 (21%); homosexual men, 76 (15%) vs. 114 (22%) (P=.006). The prevalence of HCV antibody per period was: 358 (69%) vs. 380 (58%) (P=<.001), and for the HCV-RNA was 255 (49%) vs. 240 (37%) (P=<.001). In both periods, the HCV genotype distribution was: 1, 137 (60%) vs. 138 (59%); 3, 45 (20%) vs. 42 (18%); 4, 42 (18%) vs. 47 (20%) (P=.881). CONCLUSIONS: The prevalence of HCV infection in HIV-infected patients has decreased in our area, including overall exposure to HCV virus and active infection during the last 5 years. However, the HCV genotype distribution has not changed.
BACKGROUND: The prevalence of hepatitisC is decreasing among new diagnoses of HIV/HCV coinfection in Spain. The increasing use of the HCV treatment could have changed the HCV genotype distribution. The aim of this study is to analyze changes in the prevalence of HCV coinfection and in HCV genotype distribution among HIV-infectedpatients. METHODS: A serial cross-sectional study was conducted that included all HIV-infectedpatients who attended the Outpatient Clinic of a hospital in Andalusia, between September 2008 and February 2009 (first period), and between January 2013 and June 2013 (second period). RESULTS: A total of 520 and 651 patients were included in the first and second period, respectively. The risk factors of HCV infection in the first vs. second period were: IDU, 319 (61%) vs. 348 (53%); heterosexual contact, 111 (21%) vs. 135 (21%); homosexual men, 76 (15%) vs. 114 (22%) (P=.006). The prevalence of HCV antibody per period was: 358 (69%) vs. 380 (58%) (P=<.001), and for the HCV-RNA was 255 (49%) vs. 240 (37%) (P=<.001). In both periods, the HCV genotype distribution was: 1, 137 (60%) vs. 138 (59%); 3, 45 (20%) vs. 42 (18%); 4, 42 (18%) vs. 47 (20%) (P=.881). CONCLUSIONS: The prevalence of HCV infection in HIV-infectedpatients has decreased in our area, including overall exposure to HCV virus and active infection during the last 5 years. However, the HCV genotype distribution has not changed.
Keywords:
Adicción a drogas por vía parenteral; Antivirales de acción directa; Direct-acting antiviral agents; Genotipo del virus de la hepatitis C; Hepatitis C virus; Hepatitis C virus genotype; Human immunodeficiency virus; Injecting drug use; Interferon; Interferón; Ribavirin; Ribavirina; Virus de la hepatitis C; Virus de la inmunodeficiencia humana
Authors: Karin Neukam; Pompeyo Viciana; Guillermo Ojeda-Burgos; Marcial Delgado-Fernández; María J Ríos; Juan Macías; Dolores Merino; Antonio Collado; Francisco Téllez; Juan A Pineda Journal: BMC Infect Dis Date: 2016-09-15 Impact factor: 3.090
Authors: Dubravka Salemovic; Ivana Pesic-Pavlovic; Djordje Jevtovic; Ksenija Bojovic; Jovan Ranin; Branko Brmbolic; Maja Stanojevic Journal: Arch Med Sci Date: 2017-04-20 Impact factor: 3.318
Authors: Juan Macías; Luis F López-Cortés; Francisco Téllez; Eva Recio; Guillermo Ojeda-Burgos; Maria José Ríos; Antonio Rivero-Juárez; Marcial Delgado; Juan A Pineda Journal: PLoS One Date: 2015-12-07 Impact factor: 3.240